MORGANTOWN, W.Va. and KALAMAZOO, Mich., May 4, 2017 /PRNewswire/ — Protea Biosciences Group, Inc. (OTCQB: PRGB) («Protea») and Proteos, Inc. («Proteos») announced today that they have entered into a joint co-marketing agreement.  This mutual partnership allows Protea to combine Proteos’ protein production capabilities alongside Protea’s proprietary bioanalytical services, and allows Proteos to market and promote Protea’s proprietary bioanalytical services with their custom protein production services.

«We are excited to utilize our protein characterization capabilities and workflows on the high-quality proteins and antibodies that are expressed and purified by Proteos,» stated Haddon Goodman, Vice President, Corporate Development.  He added, «Providing detailed analysis of protein structure, sequence and post-translational modifications is key to understanding important information about the proteins being produced.  This co-marketing agreement aligns with our strategy of bundling our bioanalytical capabilities with leaders in related life science and technology fields.»

Recent advancements in recombinant protein production technologies, combined with an ever-increasing understanding of biology, are discovering novel proteins at a rapid pace. These novel proteins are useful in a wide variety of biotherapeutic, industrial and diagnostic applications. With these advances comes the need for seamlessly integrating quantitative analysis of these proteins. The combined availability of the Protea and Proteos technology platforms will benefit companies and research institutions by streamlining their project development cycles. Both companies plan to actively co-market their respective capabilities to the biopharmaceutical, biotechnology, life science and academic sectors.

«It’s an absolute pleasure to be working with Protea and being able to offer comprehensive protein analysis capabilities alongside Proteos’ own protein production and purification platforms,» stated Dr. Al Darzins, President. «This partnership is likely to have significant market impact by providing our clients with a one-stop shop for the high-quality production, purification and analysis of proteins so critical for performing cutting edge biochemical research.»

About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing proprietary, bioanalytical workflows to the pharmaceutical and life science industries. «Molecular information», the generation and bioinformatic processing of very large data sets, is obtained by applying the Company’s technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms.

About Proteos Corporation:  Proteos, Inc. is a Contract Research Organization (CRO) located in Kalamazoo, MI that specializes in the production of high-quality research grade recombinant proteins for the pharmaceutical, biotechnology and life science communities. Proteos offers comprehensive protein expression and purification services, utilizing licensed mammalian, insect and bacterial expression systems. The company’s highly skilled staff has extensive experience producing many classes of recombinant proteins (i.e., antibodies, enzymes and fusion proteins). Proteos works collaboratively with its clients to design projects that are customized to meet their specifications. For more information about the company and its services, visit or call 1-269-372-3480.

Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forwardlooking statements.  Words such as «expects», «intends», «plans», «may», «could», «should», «anticipates», «likely», «believes» and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Protea is a registered trademark of Protea Biosciences Group, Inc.


To view the original version on PR Newswire, visit:

SOURCE Protea Biosciences Group, Inc.